CD BioSciences is committed to providing scientific services and technical support to our clients at multiple stages of drug discovery. Our team helps clients effectively study weak interactions and provide fragment screening services through weak affinity chromatography (WAC) technology, thereby improving the chances of successful drug development.
Fragment-based drug discovery/design (FBDD) is based on the concept of discovering small fragments (<300-350 in molecular weight) that show weak but efficient binding to target molecules (e.g. protein receptors). Since fragments inherently have a weak affinity for their targets, the development of assays with high sensitivity to affinity is important to achieve fragment screening.
A major challenge in screening weakly binding fragments is the difficulty in detecting binding interactions at equilibrium and the need to screen at high concentrations. A number of biophysical methods are available, such as MS, NMR, X-ray crystallography and SPR. Weak affinity chromatography (WAC) has recently been introduced as a new technique for fragment screening. The technique is based on the weak partitioning affinity separation of analytes (e.g. small molecules) and represents a simple and robust fragment screening technique. WAC is now a potential method for drug discovery for fragment screening due to the characteristics of sensitivity, cost-effectiveness and easily accessible.
Fig.1 Schematic demonstration of WAC-MS. (Ohlson, 2018)
Our researchers have worked to establish the WAC method and develop it into a new method for fragment screening and affinity determination in early drug discovery. Furthermore, we continually optimize our fragment screening procedures to achieve high throughput operation on standard instruments with minimal consumption of target proteins and samples. The services we offer include, but are not limited to:
Based on extensive experience in drug discovery and advanced biophysical technologies, CD BioSciences offers clients a combination of technologies to enable fragment screening. Furthermore, we continually optimize our data acquisition software to save data processing time and thus increase throughput. If you are interested in our services, please contact us to enquire about our WAC services.
CD BioSciences is a biotechnology company focused on biophysical services. We are proficient in both chemistry and biophysics, and have a comprehensive biophysical platform containing a wide range of advanced technologies.